{"content":"{\"Symbol\":[{\"ElementValue\":{\"@Type\":\"Alternate\",\"$\":\"FSP1\"},\"XRef\":{\"@Type\":\"MIM\",\"@ID\":\"182600\",\"@DB\":\"OMIM\"}},{\"ElementValue\":{\"@Type\":\"Preferred\",\"$\":\"SPG3A\"},\"XRef\":[{\"@Type\":\"MIM\",\"@ID\":\"182600\",\"@DB\":\"OMIM\"},{\"@ID\":\"5041\",\"@DB\":\"Office of Rare Diseases\"}]}],\"AttributeSet\":{\"Attribute\":{\"@Type\":\"public definition\",\"$\":\"Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a \\\"pure\\\" (\\\"uncomplicated\\\") HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome phenotype) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare.\"},\"XRef\":{\"@ID\":\"NBK45978\",\"@DB\":\"GeneReviews\"}},\"Citation\":{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"20862796\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK45978\"}]}}","id":"15930","medgen_id":"C2931355","name":"Spastic paraplegia 3","alternate_names":["Spastic Paraplegia 3A","SPG3","FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1","SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT"],"type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"606439.0001\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0009\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":\"FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1\"}","{\"db\":\"OMIM\",\"id\":\"606439.0008\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0002\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5041\",\"source_name\":\"Spastic paraplegia 3\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK45978\",\"source_name\":\"Spastic Paraplegia 3A\"}","{\"db\":\"Orphanet\",\"id\":\"100984\",\"source_name\":null}","{\"db\":\"OMIM\",\"id\":\"606439.0005\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0013\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0007\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":null}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+3/6693\",\"source_name\":\"Spastic paraplegia 3\"}","{\"db\":\"OMIM\",\"id\":\"606439.0006\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0003\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"source_name\":\"SPG3\"}","{\"db\":\"OMIM\",\"id\":\"606439.0014\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0004\",\"source_name\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}"]}
{"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Langer et al., 2012\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"22947299\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"SACHDNC, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23037933\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EASAC/FEAM, 201\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23169492\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NYMAC, 2014\",\"URL\":{\"$\":\"http://www.wadsworth.org/sites/default/files/WebDoc/68970143/DX_Guidelines_2014-10-01.pdf\"},\"CitationText\":{\"$\":\"Diagnostic Guidelines for Confirmation of Screen-Positive Newborn Screening Results\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"ACOG, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25560141\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ESHG/P3G/HUGO/PHGF, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25626707\"}},{\"@Type\":\"general\",\"@Abbrev\":\"Alpha-1 Foundation, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24121147\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NBSTRN, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24394680\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EUNENBS, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23652378\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"NSGC, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23881473\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG/ACOG/NSGC/PQF/SMFM, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25730230\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Skirton et al., 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24022298\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23619275\"}}]}","id":"32761","medgen_id":"C0950123","name":"Inborn genetic diseases","alternate_names":[],"type":"Disease","xrefs":["{\"db\":\"MeSH\",\"id\":\"D030342\",\"source_name\":null}"]}
{"content":"{\"Symbol\":{\"ElementValue\":{\"@Type\":\"Preferred\",\"$\":\"VICIS\"},\"XRef\":{\"@Type\":\"MIM\",\"@ID\":\"242840\",\"@DB\":\"OMIM\"}}}","id":"2298","medgen_id":"C1855772","name":"Vici syndrome","alternate_names":["Absent corpus callosum cataract immunodeficiency"],"type":"Disease","xrefs":["{\"db\":\"Office of Rare Diseases\",\"id\":\"448\",\"source_name\":\"Vici syndrome\"}","{\"db\":\"Orphanet\",\"id\":\"1493\",\"source_name\":null}","{\"db\":\"OMIM\",\"id\":\"242840\",\"source_name\":null}","{\"db\":\"Genetics Home Reference\",\"id\":\"vici-syndrome\",\"source_name\":\"Vici syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Absent+Corpus+Callosum+Cataract+Immunodeficiency/81\",\"source_name\":\"Absent corpus callosum cataract immunodeficiency\"}"]}
{"id":"18728","name":"See cases","alternate_names":[],"type":"PhenotypeInstruction","xrefs":[]}
{"id":"17556","medgen_id":"CN517202","type":"Disease","name":"not provided","alternate_names":[],"content":"{\"AttributeSet\":{\"Attribute\":{\"@Type\":\"public definition\",\"$\":\"The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.\"}}}","xrefs":["{\"db\":\"Developmental Genetics Unit,King Faisal Specialist Hospital & Research Centre\",\"id\":\"13DG0619\",\"source_name\":\"not provided\"}"]}
{"id":"32761","medgen_id":"C0950123","type":"Disease","name":"Inborn genetic diseases","alternate_names":[],"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Langer et al., 2012\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"22947299\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"SACHDNC, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23037933\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EASAC/FEAM, 201\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23169492\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NYMAC, 2014\",\"URL\":{\"$\":\"http://www.wadsworth.org/sites/default/files/WebDoc/68970143/DX_Guidelines_2014-10-01.pdf\"},\"CitationText\":{\"$\":\"Diagnostic Guidelines for Confirmation of Screen-Positive Newborn Screening Results\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"ACOG, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25560141\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ESHG/P3G/HUGO/PHGF, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25626707\"}},{\"@Type\":\"general\",\"@Abbrev\":\"Alpha-1 Foundation, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24121147\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NBSTRN, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24394680\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EUNENBS, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23652378\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"NSGC, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23881473\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG/ACOG/NSGC/PQF/SMFM, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25730230\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Skirton et al., 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24022298\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23619275\"}}]}","xrefs":["{\"db\":\"MeSH\",\"id\":\"D030342\",\"source_name\":null}"]}
{"id":"43188","type":"Disease","alternate_names":[],"xrefs":[]}
{"id":"16052","medgen_id":"C3279738","type":"Disease","name":"Spastic paraplegia 47, autosomal recessive","alternate_names":["adaptor protein 4 (AP-4) deficiency syndrome","Cerebral palsy, spastic quadriplegic, 5"],"content":"{\"Symbol\":[{\"ElementValue\":{\"@Type\":\"Preferred\",\"$\":\"SPG47\"},\"XRef\":{\"@Type\":\"MIM\",\"@ID\":\"614066\",\"@DB\":\"OMIM\"}},{\"ElementValue\":{\"@Type\":\"Alternate\",\"$\":\"CPSQ5\"},\"XRef\":{\"@Type\":\"MIM\",\"@ID\":\"614066\",\"@DB\":\"OMIM\"}}],\"AttributeSet\":{\"Attribute\":{\"@Type\":\"public definition\",\"$\":\"AP-4-associated hereditary spastic paraplegia (HSP), also known as AP-4 deficiency syndrome, is a group of neurodegenerative disorders characterized by a progressive, complex spastic paraplegia with onset typically in infancy or early childhood. Early-onset hypotonia evolves into progressive lower-extremity spasticity. The majority of children become non-ambulatory and usually wheelchair bound. Over time spasticity progresses to involve the upper extremities, resulting in a spastic tetraplegia. Associated complications include dysphagia, contractures, foot deformities, dysregulation of bladder and bowel function, and a pseudobulbar affect. About 50% of affected individuals have seizures. Postnatal microcephaly (usually in the -2SD to -3SD range) is common. All have developmental delay. Speech development is significantly impaired and many affected individuals remain nonverbal. Intellectual disability in older children is usually moderate to severe.\"},\"XRef\":{\"@ID\":\"NBK535153\",\"@DB\":\"GeneReviews\"}},\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"AAN/CNS, 2004\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"15037681\"}},{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"30543385\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK535153\"}]}]}","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Cerebral+palsy%2C+spastic+quadriplegic%2C+5/7944\",\"source_name\":\"Cerebral palsy, spastic quadriplegic, 5\"}","{\"db\":\"Orphanet\",\"id\":\"280763\",\"source_name\":null}","{\"db\":\"OMIM\",\"id\":\"614066\",\"source_name\":null}"]}
